{"prompt": "['Carboxymethyleellulose and Carbomer', '209510', 'Clinical Protocol v1.0', 'Principal Investigator Protocol Agreement Page', 'I confirm agreement to conduct the study in compliance with the protocol and any', 'amendments according to the current International Conference on Harmonisation Good', 'Clinical Practice (ICH GCP) guidelines.', 'I acknowledge that I am responsible for overall study conduct. I agree to personally', 'conduct or supervise the described study.', 'I agree to ensure that all associates, colleagues and employees assisting in the conduct of', 'the study are informed about their obligations. Mechanisms are in place to ensure site staff', 'receives all appropriate information throughout the study.', 'I agree to conduct this study in full conformance with the laws and regulations of the', 'country in which the research is conducted and the Declaration of Helsinki.', 'Investigator Name:', 'Investigator Qualifications:', 'PPD', 'Investigator Signature:', 'Date of Signature/Agreement:', 'DD-Mmm-YYYY', 'GlaxoSmithKline Consumer Healthcare Confidential', 'Template Version Effective: 18-May-18 (CCR #11475)', 'Page 3 of 65']['Carboxymethyleellulose and Carbomer', '209510', 'Clinical Protocol v1.0', 'Table of Contents', 'Sponsor Information', '1', 'Document History', '2', 'Principal Investigator Protocol Agreement Page', '3', 'Table of Contents', '4', '1', 'PROTOCOL SUMMARY', '9', '1.1', 'Schedule of Activities', '11', '2 INTRODUCTION', '13', '2.1', 'Study Rationale', '14', '2.2', 'Mechanism of Action/Indication', '14', '3', 'STUDY OBJECTIVES AND ENDPOINTS', '14', '4', 'STUDY DESIGN', '15', '4.1', 'Overall Design', '15', '4.2', 'Rationale for Study Design', '16', '4.3', 'Justification for Dose', '17', '4.4', 'End of Study Definition', '17', '5', 'STUDY POPULATION', '17', '5.1', 'Type and Planned Number of Subjects', '17', '5.2', 'Inclusion Criteria', '18', '5.3', 'Exclusion Criteria', '19', '5.4', 'Randomization Criteria', '19', '5.5', 'Lifestyle Considerations', '19', '5.5.1', 'Contraception', '20', '5.6', 'Screen Failures', '21', '5.7', \"Sponsor's Qualified Medical Personnel\", '21', '5.8', 'Rater/Clinical Assessor Qualifications', '21', '6', 'INVESTIGATIONAL/STUDY PRODUCTS', '21', '6.1', 'Investigational/Study Product Supplies', '22', '6.1.1', 'Dosage Form and Packaging', '23', '6.1.2', 'Preparation and Dispensing', '23', '6.2 Administration', '23', '6.2.1', 'Medication/Dosing Errors', '23', '6.3', 'Investigational/Study Product Storage', '24', '6.4', 'Investigational/Study Product Accountability', '24', '6.4.1', 'Destruction of Investigational/Study Product Supplies', '24', '6.5', 'Blinding and Allocation/Randomization', '25', '6.6', 'Breaking the Blind', '25', '6.7', 'Subject Compliance', '25', '6.8', 'Concomitant Medication/Treatment(s)', '26', 'GlaxoSmithKline Consumer Healthcare Confidential', 'Template Version Effective: 18-May-18 (CCR #11475)', 'Page 4 of 65']['Carboxymethyleellulose and Carbomer', '209510', 'Clinical Protocol v1.0', '7', 'DISCONTINUATION OF STUDY INTERVENTION AND SUBJECT', 'DISCONTINUATION/WITHDRAWAL', '26', '7.1', 'Subject Discontinuation/Withdrawal', '26', '7.2', 'Lost to Follow up', '26', '8', 'STUDY PROCEDURES', '27', '8.1', 'Visit 1/Screening', '27', '8.1.1', 'Informed Consent', '28', '8.1.2', 'Demographics', '29', '8.1.3', 'Inclusion/Exclusion Criteria', '29', '8.1.4', 'Medical History and Prior Medication/Treatment', '29', '8.1.5', 'Dental History', '29', '8.1.6', 'Subject Eligibility', '29', '8.2', 'Study Period', '29', '8.2.1', 'Visit 1/Day 1 (Baseline)', '29', '8.2.2', 'Visit 2 / Days 7+1', '30', '8.2.3', 'Visit 3 / Day 28+3', '30', '8.2.4', 'Visit 4 / Day 56+3', '31', '8.2.5', 'Visit 5 / Day 84+3', '32', '8.3', 'Diary Review', '32', '8.4', 'Study Conclusion', '33', '8.5', 'Follow-up Visit / Phone Call', '33', '9', 'STUDY ASSESSMENTS', '33', '9.1', 'Screening Assessments', '33', '9.1.1', 'Clean Dentures', '33', '9.1.2', 'Well Made Assessment', '34', '9.1.3', 'Denture Bearing Tissue Score', '34', '9.1.4', 'Well-Fit Assessment, Kapur (Olshan Modification) Index', '34', '9.2', 'Efficacy Assessments', '35', '9.2.1', 'Subject Questionnaires', '35', '9.2.2', 'Mucosal Score Assessment (MSA)', '37', '9.3', 'Safety and Other Assessments', '38', '9.3.1', 'Oral Soft Tissue (OST) Examination - Edentulous', '38', '9.3.2', 'Pregnancy Testing', '38', '10 ADVERSE EVENT AND SERIOUS ADVERSE EVENTS', '38', '10.1', 'Definition of an Adverse Event (AE)', '38', '10.2', 'Definition of a Serious Adverse Event (SAE)', '39', '10.3', 'Reporting of Adverse Events', '40', '10.3.1', 'Reporting Period', '40', '10.4', 'Reporting Procedures', '41', 'GlaxoSmithKline Consumer Healthcare Confidential', 'Template Version Effective: 18-May-18 (CCR #11475)', 'Page 5 of 65']\n\n###\n\n", "completion": "END"}